NEW YORK (GenomeWeb) - NeoGenomics today reported that its third quarter revenues increased 8 percent, just shy of Wall Street's consensus estimate. The firm also announced a change to its testing services agreement with Covance.

For the three months ended Sept. 30, revenues for the Fort Myers, Florida cancer genetic testing firm increased to $25.1 million from $23.2 million in the prior-year period. On average, analysts had expected $25.6 million in revenues.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The UK's Nuffield Council on Bioethics says genetically modifying human embryos could be morally permissible, according to the Guardian.

A new Nature Biotechnology paper reports that CRISPR-Cas9 gene editing can lead to large deletions or complex rearrangements that could be pathogenic.

The Wall Street Journal likens a prototype developed by Synthetic Genomics to a "biological fax machine."

In PNAS this week: strategy for reactivating Rett syndrome-linked MECP2, small molecules able to suppress Staphylococcus aureus virulence, and more.